Predictors of hypoglycemia in insulin-treated patients with type 2 diabetes mellitus in Basrah

Table 4 Relation of hypoglycemia during the last 3 mo with dose of insulin, family/social support, mobility, source of medications and knowledge of hypoglycemia symptoms

	Hypoglycemia in the last 3 mo		Total (n)	P value
	Yes n (%)	No n (%)
Regular dose (unit)
1-10	7 (100.0)	0 (0.0)	7	0.347
11-20	84 (80.2)	21 (19.8)	105
21-30	57 (77.0)	17 (23.0)	74
> 30	5 (62.5)	3 (37.5)	8
Total	153 (79.0)	41 (21.0)	194
Premix dose (unit)
1-10	2 (100.0)	0 (0.0)	2	0.45
11-20	78 (78.8)	21 (21.2)	99
21-30	86 (77.3)	25 (22.7)	111
> 30	10 (62.5)	6 (37.5)	16
Total	176 (77.1)	52 (22.9)	228
NPH dose (unit)
1-10	4 (100.0)	0 (0.0)	4	0.528
11-20	37 (73.1)	14 (26.9)	51
21-30	27 (66.7)	14 (33.3)	41
> 30	6 (85.7)	1 (14.3)	7
Total	74 (72.4)	29 (27.6)	103
Family/social support
Self	190 (74.8)	64 (25.2)	254	0.914
Others	51 (76.1)	16 (23.9)	67
Self and others	12 (80.0)	3 (20.0)	15
Vision
Good	203 (74.6)	69 (25.4)	272	0.560
Poor	50 (78.1)	14 (21.9)	64
Mobility
Mobile alone	223 (75.6)	72 (24.4)	295	0.698
Mobile with assistance or use wheel chair	9 (81.8)	2 (18.2)	11
Walk on stick	21 (70.0)	9 (30.0)	30
Source of medications
FDEMC1	63 (75.0)	21 (25.0)	84	0.507
Public clinic	7 (58.3)	5 (41.7)	12
Private sector	13 (72.2)	5 (27.8)	18
More than one source	170 (76.6)	52 (23.4)	222
Knowledge of hypoglycemia symptoms
Yes	246 (76.9)	74 (23.1)	320	0.003

¹Al-Faiha Specialized Diabetes, Endocrine and Metabolism Center. NPH: Neutral protamine hagedorn.